Logo

Linda Baddour, Gary Hendrickson

Sep 06, 2018

Waters announced today that has appointed Linda Baddour and Gary Hendrickson as directors of the firm.

Baddour has served as executive VP and CFO at PRA Health Sciences since 2007. Prior to PRA, she served as CFO at Pharmaceutical Product Development. Beforhand,  she also served as treasurer and chief accounting officer at the firm.

Prior to Waters, Hendrickson served as Chairman of  Valspar between 2012 and 2017, and CEO since 2011. Prior to CEO, Hendrickson acted as COO, president of several business units, and corporate VP and President of the firm's Asia Pacific branch.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.